Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future

dc.contributor.authorPark, Bomina
dc.contributor.authorCorson, Timothy W.
dc.contributor.departmentOphthalmology, School of Medicineen_US
dc.date.accessioned2019-02-22T19:33:56Z
dc.date.available2019-02-22T19:33:56Z
dc.date.issued2019-02
dc.description.abstractOcular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies. Therefore, understanding the mediators involved in their pathophysiology is necessary for the development of therapeutic strategies. To this end, the hydrolase activity of soluble epoxide hydrolase (sEH) has been explored in the context of several eye diseases, due to its implications in vascular diseases through metabolism of bioactive epoxygenated fatty acids. In this mini-review, we discuss the mounting evidence associating sEH with ocular diseases and its therapeutic value as a target. Substantial data link sEH with the retinal and choroidal neovascularization underlying diseases such as wet age-related macular degeneration, retinopathy of prematurity, and proliferative diabetic retinopathy, although some conflicting results pose challenges for the synthesis of a common mechanism. sEH also shows therapeutic relevance in non-proliferative diabetic retinopathy and diabetic keratopathy, and sEH inhibition has been tested in a uveitis model. Various approaches have been implemented to assess sEH function in the eye, including expression analyses, genetic manipulation, pharmacological targeting of sEH, and modulation of certain lipid metabolites that are upstream and downstream of sEH. On balance, sEH inhibition shows considerable promise for treating multiple eye diseases. The possibility of local delivery of inhibitors makes the eye an appealing target for future sEH drug development initiatives.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationPark, B., & Corson, T. W. (2019). Soluble epoxide hydrolase inhibition for ocular diseases: vision for the future. Frontiers in Pharmacology, 10, 95. https://doi.org/10.3389/fphar.2019.00095en_US
dc.identifier.urihttps://hdl.handle.net/1805/18461
dc.language.isoenen_US
dc.publisherFrontiersen_US
dc.relation.isversionof10.3389/fphar.2019.00095en_US
dc.relation.journalFrontiers in Pharmacologyen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/
dc.sourcePublisheren_US
dc.subjectsoluble epoxide hydrolaseen_US
dc.subjectsmall molecule inhibitoren_US
dc.subjectage-related macular degenerationen_US
dc.titleSoluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Futureen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Park_2019_soluble.pdf
Size:
2.72 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: